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ABSTRACT
The aim of the present work was to evaluate the induction and localization of Stat1, interferon (IFN) regula-
tory factor-1 (IRF-1), and IRF-2 after IFN-g exposure of human breast cancer cell lines, SKBR3, MDA468,
MCF7, and BT20. Results from growth assays, Western staining, electrophoretic mobility shift assay (EMSA),
and immunohistochemical staining were collated to test our hypothesis that immunohistochemical analysis of
Stat1, IRF-1, and IRF-2 would provide additional information about the functionality of the IFN-g signaling
pathway in human tumor lines. EMSA results showed that in each of four cell lines, Stat1 expression was in-
creased and demonstrated functional activity after IFN-g stimulation. Western and EMSA analysis showed
upregulation of IRF-1 but not IRF-2 in each cell line. Confocal microscopy of cells stained for Stat1, IRF-1,
and IRF-2 confirmed the results and also provided novel information about the intracellular localization of
proteins and intercellular variations in responses. The proportion of cells with IRF-1 stimulation and translo-
cation was positively correlated with the IFN-g growth suppression in vitro. In conclusion, using four inde-
pendent assays, we have demonstrated that heterogeneity in IFN-g-mediated upregulation of signal trans-
duction proteins can be detected in vitro and that these differences can explain distinct cellular growth effects.
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INTRODUCTION
INTERFERON-g (IFN-g) IS A PLEIOTROPIC CYTOKINE that is pro-duced by T lymphocytes and natural killer (NK) cells and
is known to have important roles in the systemic immune 
response.(1) IFN-g is involved in upregulating MHC class I
expression and inducing MHC class II expression for antigen
presentation. IFN-g also affects the monocyte/macrophage
component of the immune system by inducing differentiation,
promoting antigen presentation, and increasing expression of
cell surface proteins that augment antigen presentation.(1) Ad-
ditionally, IFN-g has significant effects on some tumors, in-
cluding tumor growth inhibition and stimulation of the immune
response to tumors.(2)
Our laboratory has shown that endogenous IFN-g limits the
in vivo growth of tumors in syngeneic mice and that blocking
the endogenous IFN-g response using anti-IFN-g antibodies
leads to an increase in the growth rate of the tumor.(3) This an-
titumor effect has been confirmed in syngeneic IFN-g knock-
out (IFN-g 2/2) mice using B16-F10 murine melanoma.(4)
These tumors grew significantly faster in the animals that lacked
the ability to produce IFN-g than in wild-type (IFN-g 1/1) mice.
The tumor growth-inhibiting effects of IFN-g have also been
demonstrated in other models.(2,5,6)
The IFN-g signal is mediated through a pathway (Fig. 1) that
includes the IFN-g receptor (IFNGR) complex, the Jak1 and
Jak2 kinases, and the signal transducer and activator of tran-
scription (Stat) protein.(1,7) Stat1 is phosphorylated, dimerizes,
and translocates to the nucleus, where the complex binds to the
promoter region of the IFN regulatory factor-1 (IRF-1) gene.
IRF-1, after transcription and translation, returns to the nucleus,
where it binds to a specific sequence in the promoter region of
IFN-g-inducible genes. These genes include CIITA, TAP1,
LMP2, b2-microglobulin, lysyl oxidase, and p21.(8) Interest-
ingly, there is an interaction of IRF-1 with IRF-2, a protein that
also can be induced by IFN-g and that also binds the same DNA
sequence as IRF-1.(9–12) Unlike IRF-1, IRF-2 downregulates or
blocks upregulation of gene transcription. IRF-2 is induced later
than IRF-1 but seems to have greater protein stability. IRF-2,
therefore, may play a role in the feedback inhibition of the ef-
fects of IFN-g mediated by IRF-1. Additionally, the ratio of
IRF-1/IRF-2 may be critical for determining some effects of
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IFN-g, analogous to the bcl2/bax ratio, which affects apopto-
sis in some circumstances.(4,13,14) IRF-1 has been shown to slow
cell growth and act as a tumor suppressor in some models, and
IRF-2 seems to have oncogenic properties.(4)
The specific aim of the present work was to evaluate the re-
sponses of Stat1, IRF-1, and IRF-2 to IFN-g in human breast
cancer cell lines using both biochemical and immunohisto-
chemical techniques. Our hypothesis is that immunohistochem-
istry and confocal microscopic analysis of Stat1, IRF-1, and IRF-
2 is an accurate way to assess the functionality of the IFN-g
signaling pathway in human tumor cell lines and that these tech-
niques may prove applicable to the human tumor specimens to
assess the intactness of this pathway in clinical breast cancer.
MATERIALS AND METHODS
Materials
Rabbit antihuman Stat1, IRF-1, or IRF-2 antibodies (Santa
Cruz Biotechnology, Sant Cruz, CA) were used for detection
in histologic studies, Western analysis, and electrophoretic mo-
bility shift assay (EMSA) studies. For histologic detection, rho-
damine red-X goat antirabbit secondary antibody was used. All
other materials were from Sigma Chemical (St. Louis, MO) un-
less otherwise noted.
Cell culture
Human SKBR3, MDA468, MCF7, and BT20 breast cancer
cell lines were used in these experiments. All media were sup-
plemented with 50 IU/ml penicillin and 50 mg/ml streptomycin.
Fetal bovine serum (FBS) was from JRH Biosciences (Lenexa,
KS). SKBR3 cells were routinely maintained in McCoy’s 5A
medium plus 10% FBS. MDA468 cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM)/Ham’s F12 (1:1)
plus 10% FBS. MCF7 cells were maintained in modified Ea-
gle’s medium (MEM) plus 10% FBS plus 1 mM sodium pyru-
vate plus 10 mg/ml bovine insulin. BT20 cells were maintained
in MEM plus 10% FBS.
MTT cell proliferation assay
The MTT cell proliferation assay was described previously.(4)
Briefly, 2 3 103 cells were plated in 200 ml appropriate medium
into the wells of 96-well plates, in the presence or absence of
100 U/ml of recombinant human IFN-g (rHuIFN-g) (PharMin-
gen, San Diego,CA) and incubated at 37°C. MTT (20 ml/well)
(5 mg/ml) (Sigma) was added to triplicate wells at various times
(0–9 days). After 24 h of incubation with MTT, the medium
was removed, and the formazan crystals were allowed to air dry
before being dissolved in mineral oil (50 ml/well) (Schnucks
Markets, Bridgeton, MO). Absorbance was measured at 595 nm
on a microplate reader (Bio-Rad, Richmond, CA).
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FIG. 1. IFN-g signal transduction pathway. IFN-g binds the IFN-g receptor proteins (IFNGR-1 and IFNGR-2), causing dimer-
ization of the receptor. This activates Jak1 and Jak2 kinases that are associated with the cytoplasmic binding sites of the receptor
proteins. These kinases phosphorylate Stat1, which dimerizes (possibly including IRF-9 in the complex) and translocates to the
nucleus. There, activated Stat1 complexes bind to the IFN-g-activated sequence (GAS), also called the IFN-g response region
(GRR), in the promoter region of the IRF-1 gene, leading to transcription of the IRF-1 gene. After translation, IRF-1 migrates to
the nucleus and binds to the IRF-binding element (IRF-E), promoting transcription of IFN-g-responsive genes. Although IRF-2
also has GAS regions in its promoter, it is less significantly induced by activated Stat1 binding. It also has a longer half-life in the
cytoplasm than IRF-1. Constitutive rather than induced IRF-2 activity thus seems to account for most expressed IRF-2. IRF-2 also
binds to the IRF-E but does not promote transcription and thus acts as a competitive inhibitor of IRF-1-induced transcription.
Cell extracts
Whole cell extracts were obtained from trypsinized subcon-
fluent monolayers of cells and prepared as described by Harada
et al.(15) Briefly, pelleted cells were suspended in 4 3 volume
of lysis buffer (20 mM HEPES, pH 7.9,1 50 mM NaCl, 10 mM
EDTA, 2 mM EGTA, 10 mM molybdate, 10 mM vanadate, 100
mM NaF, 0.1% NP40, 0.5 mM PMSF, 100 mg/ml leupeptin),
sonicated for 2 min, then centrifuged at 10,000 rpm for 10 min.
The supernatant was used as cell extract.
Western immunoblotting
Subconfluent cells were stimulated for various times with
IFN-g (100 U/ml), and whole cell protein was isolated as de-
scribed. The protein concentration was determined by a Brad-
ford-based colorimetric assay (Bio-Rad). Equal amounts of pro-
tein from the various treatment groups were separated by elec-
trophoresis within an SDS polyacrylamide gel, blotted on ni-
trocellulose, and then probed with specific antibodies for human
Stat1, IRF-1, and IRF-2 (Santa Cruz Biotechnology). The blot
was then probed with specific horseradish peroxidase (HRP)-
linked secondary antibodies and developed using the ECL De-
veloper kit (Amersham Life Science, Arlington Heights, IL).
EMSA
Whole cell extracts (15 mg/sample) were mixed with 32P-la-
beled oligomer (C13 for IRF-1 and IRF-2(16), GRR for Stat1(17);
,1.5 pmol/sample, 50,000–200,000 cpm/sample), 1 mg herring
sperm DNA, and 2 mg poly(dI:dC) and incubated at 25°C for 60
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FIG. 2. MTT cell proliferation assay. Breast cancer cells (2 3 103) were plated in 96-well plates with or without IFN-g. At
various times (0–9 days), 20 ml/well of MTT was added to triplicate wells, stopping further growth. MTT reduction is propor-
tional to the viable cell number. At the end of the experiment, the resulting formazan crystals were dissolved in mineral oil, and
the density was measured at 595 nm. Where standard error bars are not visible, they fall within the symbol.
min in a final volume of 10 ml buffer containing 10 mM Tris-
HCl, pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, and 5%
glycerol. Some extracts were preincubated with 1 ml antibody
(anti-IRF-1 or anti-IRF-2, 1 mg/ml) at 0°C for 60 min before mix-
ing with oligomer. The IRF-1 antibody is an affinity-purified rab-
bit polyclonal antibody raised against a peptide representing
amino acids 306–325 of the carboxyl-terminus. This antiserum
is not cross-reactive with IRF-2 or IFN-stimulated gene factor
3a (ISGF-3a). The IRF-2 antibody is an affinity-purified rabbit
polyclonal antibody raised against a peptide corresponding to
amino acids 331–348 mapping at the carboxyl-terminus that does
not cross-react with IRF-1 or ISGF3a. Because these antibodies
are specific for the carboxyl-terminus, they do not interfere with
DNA binding and thus can create supershifted complexes on au-
toradiographs. The samples were run on preelectrophoresed non-
denaturing 4% polyacrylamide gels and autoradiographed.
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FIG. 4. Stat1 activity is upregulated after IFN-g stimulation. EMSA of SKBR3 (A) and MDA468 (B) whole cell lysates. Ex-
tracts were probed with a Stat1-specific 32P-labeled GRR oligomer (A, B, C, D) after stimulation (or not) with IFN-g (100 U/ml)
for the indicated times. Some IFN-g-stimulated samples were preincubated with 1 ml anti-Stat1 antibody (lane ss, supershift).
FIG. 3. Western blots show that IRF-1 but not IRF-2 was increased in IFN-g-stimulated cell lines. Western blots of SKBR3,
MDA468, MCF7, and BT20 whole cell lysates after cells were or were not stimulated with IFN-g (100 U/ml for 6 h). After elec-
trophoresis on 12% polyacrylamide/SDS gels and transfer to nitrocellulose membranes, proteins were probed with anti-IRF-1 an-
tibody (top) or with anti-IRF-2 antibody (bottom). Detection was done using ECL and exposure to ECL Hyperfilm. For optimal
detection, 10 mg total protein was loaded at top, and 50 mg total protein was loaded at bottom.
Immunohistochemistry (IHC)
Cells were grown overnight on chamber slides (Nunc, Inc.,
Naperville, IL) in appropriate medium for 24 h in a 37°C, ster-
ile incubator. Cells were incubated with or without IFN-g (100
U/ml, 1 h for Stat1, 6 h for IRF-1 and IRF-2), then fixed (10
min) using freshly made 2% paraformaldehyde, and permeabi-
lized (0.3% Triton-X 100, 3 min). Tissues were incubated with
a blocking buffer (5% goat serum in 1% bovine serum albumin
[BSA] in phosphate-buffered saline [PBS] for 1 h at ambient
temperature) to inhibit nonspecific protein binding. Next, tis-
sues were incubated with antibody (overnight at 4°C for Stat1
and for 1 h at ambient temperature for IRF-1 and IRF-2), and
the concentration of primary antibody was determined in titra-
tion studies. Fluorescent-labeled secondary antibody was rou-
tinely added for 30 min at a dilution determined in titration stud-
ies. Excess secondary antibody was rinsed off, and a slow-fade
mounting medium, Vectashield (Vector Labs, Burlingame,
CA), was added. The cells were covered with glass coverslips.
Control slides received no primary antibody. Stained cells were
viewed, and images were recorded using a Bio-Rad Radiance-
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FIG. 5. EMSA analysis of IRF-1 and IRF-2 response to IFN-g stimulation. Cells were probed for IRF-1 and IRF-2 (A, B, C, D)
expression with or without IFN-g (100 U/ml) incubation for 6 h. Whole cell extracts were probed with a 32P-labeled C13 oligomer
(part of the DNA binding domain in the promoter region of genes to which IRF-1 and IRF-2 competitively bind). Thus, under
conditions of excess 32P-labeled C13 oligomer, both IRF-1 and IRF-2 will bind to the probe. In this experiment, lanes are iden-
tified by the band remaining after supershift (ss) with antibody specific to either IRF-1 or IRF-2. Lane 1 in all cell lines is the
band remaining after sample has been preincubated with anti-IRF-2. Therefore, the band is IRF-1, as labeled.
Plus/Nikon E800 Confocal Microscope (excitation 514 nm,
emission 570 nm) with LaserSharp 2000 software. Image anal-
ysis was made on recorded images by qualitative assessment of
random fields to give data on a minimum of 100 cells per slide.
RESULTS
Figure 2 shows growth curves for the four breast cancer cell
lines focused on in this study, each grown in the presence and
absence of IFN-g. IFN-g had no effect on cell growth in SKBR3
and MCF7 cells. BT20 cells showed a maximum of 30% growth
inhibition when IFN-g was present. Growth of MDA468 cells
was dramatically and rapidly inhibited by IFN-g (8% and 19%
inhibition on days 2 and 3, respectively, and 80% inhibition by
day 9).
To evaluate the integrity of the IFN-g signaling pathway in
each of these breast cancer cell lines, we examined Stat1, IRF-
1, and IRF-2 by Western analysis, EMSA, and confocal mi-
croscopy. Figure 3 demonstrates by Western blots that IRF-1
but not IRF-2 protein expression is increased in IFN-g-stimu-
lated cells. IRF-2 appears to be constitutively expressed in all
four cell lines at levels less than those for IRF-1 in IFN-g-stim-
ulated cells, or the IRF-2 Western blot is substantially less sen-
sitive than the IRF-1 blot. In fact, in order to detect IRF-2 in
Western blots, it was necessary to load 5 times the total pro-
tein per lane that was loaded for IRF-1 detection (50 mg vs. 10
mg, respectively). Western results for cells stimulated for 15
and 24 h with IFN-g were similar to the results at 6 h for each
respective cell line (data not shown).
EMSA analysis of the four cell lines confirms and extends
the Western results. Stat1 expression is increased after IFN-g
stimulation, and further, this protein has functional activity (im-
plying phosphorylation and dimerization), recognizing and
binding to the GRR oligomer, which is part of the consensus
promoter sequence recognized by Stat1 (Fig. 4). The specificity
of the DNA probe binding is confirmed by the decrease in the
Stat1 band when lysates from IFN-g-stimulated cells were
preincubated with anti-Stat1 antibody (Fig. 4, supershift [ss]
lane). EMSA results are concordant with Western results for
IRF-1, demonstrating significant upregulation of IRF-1 ex-
pression after IFN-g stimulation in all four cell lines (Fig. 5).
Small amounts of baseline IRF-1 are demonstrated in SKBR3,
MDA468, and BT20 cells but not in MCF7 cells, and there is
a marked increase in IRF-1 binding to the C13 probe after IFN-
g stimulation. Faint IRF-2 bands are seen in unstimulated cells.
In contrast to IRF-1, IFN-g stimulation does not substantially
increase the amount of IRF-2 binding to the probe for any cell
line. In these EMSA experiments, an equal amount of cell lysate
was loaded in each lane.
In all confocal experiments, control slides were run that re-
ceived no primary antibody. In each experiment, these control
slides showed no background binding (results not shown). Con-
focal micrographs revealed baseline Stat1 expression localized
in the cytoplasm in each of the four cell lines (Figs. 6A, 7A,
8A, and 9A). On stimulation with IFN-g, Stat1 relocated in the
nucleus in each of the four cell lines (Figs. 6B, 7B, 8B, and
9B), implying phosphorylation and dimerization. This is in
agreement with the EMSA results demonstrating binding func-
tion (Fig. 4). Although the EMSA results showed that Stat1
can bind to its nuclear consensus sequence, the combination
of EMSA and the confocal images showed both Stat1 trans-
port into the nucleus and DNA binding, confirming the func-
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FIG. 7. Immunohistochemistry of MDA468 breast cancer cells
in vitro. (A, C, E) Unstimulated cells. (B, D, F) Cells stimulated
with IFN-g (100 U/ml for 6 h at 37°C). (A and B) Anti-Stat1 an-
tibody (C and D) Anti-IRF-1 antibody. (E and F) Anti-IRF-2 an-
tibody. (A, B, C, D, E, F) Rhodamine red X goat antirabbit IgG
secondary antibody. Stimulation of MDA468 cells with IFN-g
caused upregulation and transport to the nucleus of Stat1 and
IRF-1 in all cells but no nuclear IRF-2 detection.
FIG. 6. Immunohistochemistry of SKBR3 breast cancer cells
in vitro. (A, C, E) Unstimulated cells. (B, D, F) Cells stimu-
lated with IFN-g (100 U/ml for 6 h at 37°C). (A and B ) Anti-
Stat1 antibody. (C and D) Anti-IRF-1 antibody. (E and F) Anti-
IRF-2 antibody. (A, B, C, D, E, F) Rhodamine red X goat
antirabbit IgG secondary antibody. Stimulation of SKBR3 cells
with IFN-g caused upregulation and transport to the nucleus of
Stat1 in all cells, a mixed nuclear response of IRF-1, and no
nuclear IRF-2 detection.
tionality of Stat1 after IFN-g stimulation for each of the four
cell lines.
IRF-1 was expressed in each of the four cell lines before IFN-
g stimulation (Figs. 6C, 7C, 8C, and 9C) and was primarily lo-
calized diffusely in the cytoplasm. BT20 cells were the excep-
tion, with a subpopulation of cells showing nuclear as well as
cytoplasmic staining. After IFN-g stimulation, IRF-1 expression
was increased in SKBR3 and MDA468 cells and activated in
each of the four cell lines, as shown by nuclear translocation
(Figs. 6D, 7D, 8D, and 9D). However, there were degrees of ex-
pression and translocation, with MDA468 and BT20 demon-
strating uniform nuclear staining compared with SKBR3 and
MCF7 cells (Table 1). MCF7 cells appeared quite heterogeneous
in their IRF-1 expression patterns, with subsets of cells showing
little baseline IRF-1 and no nuclear localization (Fig. 8C, D).
IRF-2 was present in the cytoplasm of all four cell lines be-
fore IFN-g stimulation (Figs. 6E, 7E, 8E, and 9E). No nuclear
translocation of IRF-2 was seen in any of the cell lines with
IFN-g treatment (Figs. 6F, 7F, 8F, and 9F), suggesting that the
IRF-2 by EMSA represented cytoplasmic IRF-2 capable of
DNA binding but that this IRF-2 did not get transported to the
nucleus. Alternatively, the amount of IRF-2 in the nucleus could
be below the detection threshold of immunohistochemistry and
confocal microscopy.
Table 1 summarizes our quantitative analysis of the entire
population of cells observed with confocal microscopy for each
cell line as a function of stimulation time with IFN-g. BT20
cells were the most enigmatic, showing both Stat1 and IRF-1
staining in the nucleus without IFN-g stimulation. MDA468,
SKBR3, and MCF7 did not show any nuclear staining without
IFN-g. With IFN-g stimulation, MDA468 cells showed that
.80% of the cells had strong nuclear staining for IRF-1, and
this pattern did not vary as a function of IFN-g incubation time.
Whereas BT20 cells showed 94% of the population to have
IRF-1 nuclear staining after 6 h of IFN-g stimulation, these
numbers decreased to 60% and 82% after 15 and 24 h, respec-
tively, of IFN-g stimulation. For all the confocal experiments
described, control cells with no primary antibody added showed
only minimal background staining by secondary antibody (data
not shown).
In summary, three independent assays detected IFN-g-me-
diated upregulation of signal transduction proteins in vitro. Fur-
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FIG. 8. Immunohistochemistry of MCF7 breast cancer cells
in vitro. (A, C, E) Unstimulated cells. (B, D, F) Cells stimu-
lated with IFN-g (100 U/ml for 6 h at 37°C). (A and B) Anti-
Stat1 antibody. (C and D) Anti-IRF-1 antibody. (E and F) Anti-
IRF-2 antibody. (A, B, C, D, E, F) Rhodamine red X goat
anti-rabbit IgG secondary antibody. Stimulation of MCF7 cells
with IFN-g caused upregulation and transport to the nucleus of
Stat1, a heterogeneous nuclear accumulation of IRF-1, and no
nuclear IRF-2 response.
FIG. 9. Immunohistochemistry of BT20 breast cancer cells
grown in vitro. (A, C, E) Unstimulated control cells. (B, D, F)
Cells stimulated with IFN-g (100 U/ml for 6 h at 37°C). (A and
B) Anti-Stat1 antibody. (C and D) Anti-IRF-1 antibody. (E and
F) Anti-IRF-2 antibody. (A, B, C, D, E, F) Rhodamine red X
goat antirabbit IgG secondary antibody. Stimulation of BT20
cells with IFN-g caused upregulation and transport to the nu-
cleus of Stat1 and IRF-1 but not IRF-2.
ther, confocal microscopy studies have enabled us to document
the translocation of specific proteins from the cytoplasm to the
nucleus and to obtain an overview of the heterogeneity of re-
sponses to IFN-g in cancer cell populations. The heterogeneity
of nuclear expression of IRF-1 at 6 h in these cell lines corre-
lated with the in vitro growth sensitivity to IFN-g.
DISCUSSION
In addition to its antiviral properties, IFN-g appears to be a
pivotal part of the endogenous immune response to tumors. In
tumors that become clinically evident, the tumor cells have de-
veloped ways to evade the immune response, and among these
may be changes in the way that the tumor processes endoge-
nous IFN-g signals. Shankaran et al.(2) demonstrated that car-
cinogen-induced sarcomas differed between those induced in
immunologically intact mice and those induced in mice with-
out either T cells (RAG2 mice) or IFN-g (IFN-g 2/2 mice) sig-
naling. Not only did the mice that were immunologically im-
paired develop tumors with greater frequency, but they also
developed tumors that lacked resistance to IFN-g-based im-
munity when transplanted into normal mice. These authors pro-
posed that immunoediting of the tumors induced in the im-
munologically intact mice had made the tumors that did grow
resistant to the effects of IFN-g.(2) In contrast, the tumors in-
duced in the RAG2 knockout mice were susceptible to this an-
titumor immune response in normal mice, presumably because
they had never been exposed to the immunologic pressure.
We have proposed previously that this immunoediting effect
must exist in human tumors, as they generally arise in individ-
uals with intact immune systems and somehow must escape the
endogenous immune system, including IFN-g signals, to be-
come clinically evident.(3,18,19) To investigate this, we studied
archival human breast tumor specimens to look for evidence of
IFN-g signal transduction by evaluating IRF-1 expression. We
compared immunohistochemical expression of IRF-1 protein in
normal breast tissue, preinvasive breast cancer, and invasive
breast cancer(19) and demonstrated by IHC that nearly all nor-
mal breast epithelial tissue expressed IRF-1. In contrast, such
expression was less frequent in preinvasive cancers and corre-
lated with tumor grade. Invasive cancers expressed IRF-1 even
less frequently, as did cancers with lymph node metastases.
Based on these findings, we sought in the present study to in-
vestigate the signal transduction response to IFN-g in vitro in
human breast cancer cell lines, anticipating differences in the
way distinct tumor cell lines would process the IFN-g signal.
We have evaluated the downstream components of the IFN-g
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TABLE 1. SUMMARY OF CONFOCAL MICROSCOPY EXPERIMENTSa,b
Time points
0 1 h 6 h 15 h 24 h
SKBR3
Stat 1 Cyto Nucleus
IRF-1 100% cyto NA 35% cyto 72% cyto 55% cyto
65% nuclear 28% nuclear 45% nuclear
IRF-2 100% cyto NA 100% cyto 100% cyto 100% cyto
MDA468
Stat 1 Cyto Nucleus
IRF-1 100% cyto NA 19% cyto 16% cyto 16% cyto
81% nuclear 84% nuclear 84% nuclear
IRF-2 100% cyto NA 100% cyto 100% cyto 100% cyto
MCF7
Stat 1 Cyto Nucleus
IRF-1 100% cyto NA 64% cyto 70% cyto 61% cyto
36% nuclear 30% nuclear 39% nuclear
IRF-2 100% cyto NA 100% cyto 50% cyto 100% cyto
50% nuclear
BT20c
Stat 1 30% 100%
nuclear nuclear
IRF-1 34% cyto NA 6% cyto 40% cyto 18% cyto
166% nuclear 114% nuclear 139% nuclear 149% nuclear
110% nuclear 1180% nuclear 1121% nuclear 1133% nuclear
IRF-2 100% cyto NA 100% cyto 100% cyto 100% cyto
aSummary of the data shown in Figures 6, 7, 8, 9. Staining as described in Materials and Methods. All experiments were per-
formed in duplicate.
bThe percent of cells reported as cytoplasmic (cyto) staining had no nuclear staining. The percent reported as nuclear had both
nuclear and cytoplasmic staining.
cIn BT20 cells, nuclear staining was not uniform as in the other cell lines, and this heterogeneity is reflected by assigning 1
or 11 to the subpopulations.
pathway, starting at Stat1 and working distally to IRF-1 and
IRF-2. Stat1 expression and activity appeared to be similar in
each of the cell lines. Each of the four tumor lines showed ba-
sal cytoplasmic expression of Stat1, with no Stat1 in the nu-
cleus and no binding activity for the GAS consensus sequence.
However, each cell line showed a dramatic induction of GAS
sequence binding activity within 5 min of IFN-g exposure
(EMSA) and translocation of the Stat1 activity to the nucleus
(microscopy). These results indicate to us that all these cell lines
have intact cell surface receptor complexes and Jak1 and Jak2
kinases that are capable of transducing the IFN-g signal.
IRF-1 is the main transcription factor responsible for the pro-
motion of gene transcription by IFN-g. We have shown previ-
ously that IRF-1 overexpression in tumor cells has dramatic ef-
fects on tumor cell growth both in vitro and in vivo.(20)
Overexpression of IRF-1 suppresses the malignant phenotype,
dramatically slows cell growth, and can make nonimmunogenic
tumors immunogenic, conferring resistance not only to subse-
quent challenge to the IRF-1-overexpressing tumor but also to
the more aggressive and nonimmunogenic parent cell line. For
these reasons, we have hypothesized that expression and local-
ization of IRF-1 would be a particularly likely locus for alter-
ation in tumor cells, as diminishing the effects of IRF-1 could
produce substantial survival benefits for the tumor.
In this study, in general, we found IRF-1 staining at base-
line in resting tumor cells but, except for BT20, only in the cy-
toplasm, and EMSA evaluation showed very little binding ac-
tivity. Within 6 h of IFN-g stimulation, IRF-1 protein was
markedly induced (Western) and located in the nucleus (mi-
croscopy), with dramatic increases in the IRF-E binding activ-
ity in all cell lines (EMSA). However, there were some signif-
icant differences in the uniformity of expression. The techniques
that pool tumor cells to demonstrate their responses (Western
and EMSA) showed no differences between the cell lines whose
growth was affected by IFN-g and those that were not affected.
Microscopy revealed, however, that the IRF-1 response to IFN-
g is heterogeneous in some cell lines. In SKBR3 and MCF7
cell lines, some cells showed dramatic nuclear staining,
whereas other cells had little or no IRF-1 in the nucleus. This
was in marked contrast to the more homogeneous nuclear stain-
ing of MDA468 and BT20 cells. These differences correlated
with the growth-inhibitory effects of IFN-g, as the cell lines
that responded to IFN-g with dramatic growth slowing (Table
1) had intense and uniform IRF-1 nuclear staining, whereas the
cell lines that did not respond had heterogeneous nuclear stain-
ing. Only the technique of IHC staining with confocal mi-
croscopy was able to delineate these physiologic and popula-
tion differences.
IRF-2 is a protein that has sequence and structural similari-
ties to IRF-1 and binds the same DNA sequence, a segment of
the IRF-E.(8–11,15) We have demonstrated previously the in vivo
and in vitro tumor-promoting effects of IRF-2 in a murine
model, where overexpression of IRF-2 made tumors insensitive
to IFN-g growth suppression in vitro and increased tumor
growth rate in vivo.(4) This is consistent with other studies that
have identified an oncogenic effect of IRF-2.(21) In studies of
archival human breast cancer specimens, we found that IRF-2
is infrequently expressed in normal breast tissue (2 of 31 spec-
imens) and that expression increases in frequency in low-grade
ductal carcinoma in situ (DCIS) (3 of 11 specimens), high-grade
DCIS (14 of 22 specimens), and invasive carcinoma (28 of 49
specimens),(19) implying that IRF-2 might be involved in the
transformation of normal breast epithelium to cancer. We hy-
pothesized that IRF-2 protein levels in the tumor cell lines might
be involved in the resistance of cell lines to the effects of in-
duced IRF-1.
We did not find convincing evidence of differences in IRF-2
basal expression, induced expression, or localization in these
studies. Each cell line has basal IRF-2 expression, and there
was not convincing induction of further IRF-2 expression for
any of the four cell lines. Confocal microscopy revealed the ex-
pression to be mainly cytoplasmic, although there was some
nuclear staining as well. Although these investigations did not
reveal any differences between the cell lines regarding IRF-2
expression that could explain the spectrum of IFN-g growth ef-
fects, the expression of IRF-2 in each tumor line was consis-
tent with our previous studies.
In summary, these studies demonstrated the heterogeneity of
breast cancer tumor cell responses to IFN-g, both in antiprolif-
erative effects and in the induction of IRF-1. The intactness of
the proximal signaling cascade in these cell lines was clear from
their robust and uniform activation of Stat1. The differences be-
tween the cell lines appeared distal to Stat1, at the level of IRF-1
expression and nuclear translocation, which is heterogeneous
in the unresponsive cell lines. IRF-2, although expressed by
each of the four cell lines, did not respond significantly in ei-
ther expression or localization. The root of this heterogeneity
of IRF-1 stimulation by IFN-g remains to be explored.
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